Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Ajjai S Alva"'
Autor:
Jean-Christophe Brisset, Benjamin A Hoff, Thomas L Chenevert, Jon A Jacobson, Jennifer L Boes, Stefanie Galbán, Alnawaz Rehemtulla, Timothy D Johnson, Kenneth J Pienta, Craig J Galbán, Charles R Meyer, Timothy Schakel, Klaas Nicolay, Ajjai S Alva, Maha Hussain, Brian D Ross
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0123877 (2015)
Bone metastasis occurs for men with advanced prostate cancer which promotes osseous growth and destruction driven by alterations in osteoblast and osteoclast homeostasis. Patients can experience pain, spontaneous fractures and morbidity eroding overa
Externí odkaz:
https://doaj.org/article/4f5abe73610c40c2b93fec33f6a9b7b2
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Ocular immune-related adverse events are a relatively rare complication of immune checkpoint inhibitors. Common ocular toxicities range from dry eyes to inflammatory uveitis and ocular myasthenia gravis. Here, we present the case of a 55-year-old wom
Externí odkaz:
https://doaj.org/article/f5e9c2351f8d4e66b8403d6f5064d5e7
Autor:
Charles B. Nguyen, Ajjai S. Alva
Publikováno v:
Advances in Oncology. 3:129-136
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c66eabed8bc8024dfd009788e761d0c3
https://doi.org/10.1016/j.yao.2023.01.009
https://doi.org/10.1016/j.yao.2023.01.009
Autor:
Vincent T. Ma, Charles S. Katzman, Phillip L. Palmbos, Rajiv M. Patel, Johann E. Gudjonsson, Ajjai S. Alva
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 1, Iss , Pp 100004- (2020)
Immune-mediated cutaneous reactions are a frequent occurrence in cancer patients treated with immune checkpoint inhibitors. A small subset of these adverse events are psoriasiform reactions. To date, there is no high-level evidence supporting the mos
Externí odkaz:
https://doaj.org/article/b542242dacf0436baa4cc6c44c36c7f7
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss , Pp 100251- (2020)
Introduction: Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal cell carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry a poor prognos
Externí odkaz:
https://doaj.org/article/9762f402e20a46e09a12e8c70dd1c421
Autor:
Arul M. Chinnaiyan, A. Robert MacLeod, Youngsoo Kim, Ajjai S. Alva, Xuhong Cao, Alice Xu, Kristin M. Juckette, Andrew Delekta, Esther Luo, Xiaojun Jing, Fengyun Su, Heng Zheng, Xiaoju Wang, Sudhanshu Shukla, Yuanyuan Qiao, Lisha Wang, Yajia Zhang, Abhijit Parolia, Mengyao Tan, Josh Vo, Jean C. Tien, Lanbo Xiao
Supplementary Table 1: List of the compounds in the epigenetic inhibitor library.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0056b26f4599a31c81525a93542a9cb
https://doi.org/10.1158/0008-5472.22419987.v1
https://doi.org/10.1158/0008-5472.22419987.v1
Autor:
Arul M. Chinnaiyan, A. Robert MacLeod, Youngsoo Kim, Ajjai S. Alva, Xuhong Cao, Alice Xu, Kristin M. Juckette, Andrew Delekta, Esther Luo, Xiaojun Jing, Fengyun Su, Heng Zheng, Xiaoju Wang, Sudhanshu Shukla, Yuanyuan Qiao, Lisha Wang, Yajia Zhang, Abhijit Parolia, Mengyao Tan, Josh Vo, Jean C. Tien, Lanbo Xiao
This file includes Supplementary Figures S1-S8. Figure S1: Inhibition of EPZ6438 and ASO-EZH2 sensitizes enzalutamide-resistant LNCaP cells to enzalutamide or ASO-AR. Figure S2: Design and validation of sgRNA targeting EZH2. Figure S3: Growth inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b74e293913dbca7b62487c878666eba
https://doi.org/10.1158/0008-5472.22419990.v1
https://doi.org/10.1158/0008-5472.22419990.v1
Autor:
Arul M. Chinnaiyan, A. Robert MacLeod, Youngsoo Kim, Ajjai S. Alva, Xuhong Cao, Alice Xu, Kristin M. Juckette, Andrew Delekta, Esther Luo, Xiaojun Jing, Fengyun Su, Heng Zheng, Xiaoju Wang, Sudhanshu Shukla, Yuanyuan Qiao, Lisha Wang, Yajia Zhang, Abhijit Parolia, Mengyao Tan, Josh Vo, Jean C. Tien, Lanbo Xiao
Supplementary information with additional materials and methods, references, and the legends for all supplementary figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae87a07609a8acae31b96f5c8d4555b
https://doi.org/10.1158/0008-5472.22419996.v1
https://doi.org/10.1158/0008-5472.22419996.v1
Autor:
Arul M. Chinnaiyan, A. Robert MacLeod, Youngsoo Kim, Ajjai S. Alva, Xuhong Cao, Alice Xu, Kristin M. Juckette, Andrew Delekta, Esther Luo, Xiaojun Jing, Fengyun Su, Heng Zheng, Xiaoju Wang, Sudhanshu Shukla, Yuanyuan Qiao, Lisha Wang, Yajia Zhang, Abhijit Parolia, Mengyao Tan, Josh Vo, Jean C. Tien, Lanbo Xiao
Advanced prostate cancer initially responds to androgen deprivation therapy (ADT), but the disease inevitably recurs as castration-resistant prostate cancer (CRPC). Although CRPC initially responds to abiraterone and enzalutamide, the disease invaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f2c3a2f68aa78b18e9a1b8942680041
https://doi.org/10.1158/0008-5472.c.6510525.v1
https://doi.org/10.1158/0008-5472.c.6510525.v1
Autor:
Scott A. Tomlins, Daniel R. Rhodes, Kathleen R. Cho, Paul D. Williams, Santhoshi Bandla, Seth Sadis, Javed Siddiqui, Jeffrey S. Montgomery, Todd M. Morgan, Ajjai S. Alva, Felix Y. Feng, Rohit Mehra, Alon Z. Weizer, Yajia Zhang, Yali Zhai, Chia-Jen Liu, Andi K. Cani, Daniel H. Hovelson, Andrew S. McDaniel
Description of additional methods and procedures used in the study. Also includes Supplementary References.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0861852fd29d4af3a48d0bb7cdd01393
https://doi.org/10.1158/0008-5472.22406991.v1
https://doi.org/10.1158/0008-5472.22406991.v1